Physician profile
Albert Fleisher
NPI 1710971254
$1,045.46
in general payments reported to CMS, 2019-2025
12 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.89 · 2022: $75.31 · 2023: $77.85 · 2024: $443 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $288.01 | 2023-2024 | Gastrointestinal Videoscope, Visiglide, Evis Exera III Colonovideoscope |
| Boston Scientific Corporation | $163.71 | 2023-2025 | General - Biliary Devices, Exalt Model D |
| Phathom Pharmaceuticals, INC. | $115.50 | 2024-2025 | Voquezna |
| Abbvie INC. | $113.53 | 2024-2025 | |
| Medtronic, INC. | $75.31 | 2022 | |
| Pfizer INC. | $65.77 | 2025 | |
| Madrigal Pharmaceuticals | $59.60 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $52.33 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $35.55 | 2025 | Vowst |
| Micro-Tech Endoscopy USA, INC. | $26.29 | 2024 | Eyemax |
| Takeda Pharmaceuticals U.S.A., INC. | $24.97 | 2025 | Eohilia |
| Covidien Lp | $24.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Fleisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.